Where Big Ideas & Smart Risks Drive Medical Breakthroughs
Genesys Snapshot
Unblinding the Future: From Seed to Patient Impact
We invest and build companies in the high growth sectors of biotechnology, pharmaceuticals and medical technology.
For over 25 years, we have been investing at the leading edge of medical innovation and have a proven track record of identifying emerging bioscience opportunities and transforming them into commercially successful companies.
The Genesys Advantage
We have over 25 years of continuous successful partnership that forms the backbone of our firm, making Genesys one of the most experienced healthcare investment teams in North America.
Long-standing partnerships with leading North American research institutes and universities give us early access to top-tier discoveries, high-potential deal flow, and unparalleled diligence expertise.
Leveraging our local world-class research corridor, we become thought partners to scientific founders and entrepreneurs and work closely with them to create and build pioneering companies that will shape the future of healthcare.
Our proven investment strategy and differentiated deal flow have driven repeatable class-leading returns for our investors while also advancing medicine for millions of patients.
Powered by partnership
“If you are an early-stage biotech company looking for investors who will roll up their sleeves and work with you to build a great company, Genesys is the right partner for you. They will not only be there as you work to launch your company but they will also put in a lot of sweat equity along the way to help you achieve your long-term goals.”
“All founders hope for a partner who brings out their best—the Genesys team was that for us. They added structure, clarity, and confidence at exactly the moments we needed them most. Their steady hand shaped our board, our capital strategy, and our growth as an executive team.”
“Genesys has been a committed partner in Feldan’s growth, offering not only investment but also valuable strategic guidance. Their deep scientific and market knowledge, strong network, and solid reputation have already made a meaningful impact. Their insights and support have also been invaluable to me as a CEO, helping navigate governance, key decisions, and the challenges of building a biotech company.”
“Genesys is unique in its investment appetite for early stage risk and the unwavering support that it provides to start-up management teams. I was happy to have them on board as we built Inversago together and look forward to working together again.”
“Genesys Capital is a very focused investor. They only invest in early-stage life sciences companies. As a CEO, I view Genesys as a partner in problem solving, fund raising and business development. Genesys is very well respected throughout Canada and the USA. I have attended the JP Morgan conference in San Francisco for several years now and I continue to be impressed with the breadth of Genesys network. Let the Genesys team understand the good, bad and ugly parts of your business - this is where they provide outstanding advice and solutions.”
"I have enjoyed a fruitful relationship with Genesys for over 25 years. Genesys first invested in Epocal in 2000 and I appreciated their support and commitment all throughout the company’s journey until its final sale to Alere, now Siemens. When I decided to launch my next start-up Questat in 2020, Genesys was the first call I made. I am pleased to be working with the Genesys team again and look forward to our future success with the Questat venture."
Catalysts for Medical Breakthroughs
At Genesys, relationships come first. With over 25 years of investment experience combined with deep life sciences knowledge, an investment from us is an enduring commitment to meaningful collaboration as we solve some of the worlds most pressing unmet medical needs together.
Partnering with Visionaries to Advance Life-Saving Innovation
Selected stories of portfolio companies where Genesys has helped to create, build and enable.
From Creation to Exit: The Inversago Origin Story
Inversago acquired by Novo Nordisk for $1.1B USD
Inception to Anchor Company: The Fusion Origin Story
Fusion acquired by Astra Zeneca for $2.4B USD
Current Investments
Functional.jpg)
Past Success
